Korean J Obstet Gynecol.  2006 Dec;49(12):2597-2603.

Growth Inhibitory Effect of Resveratrol on Uterine Leiomyoma Cells

Affiliations
  • 1Department of Obstetrics and Gynecology, School of Medicine, Keimyung university, Daegu, Korea. ysd7505@dsmc.or.kr

Abstract


OBJECTIVE
To examine the effect of resveratrol on cell proliferation and cell cycle progression in the human uterine leiomyoma cells.
METHODS
MTS [3-(4,5-dimethylthiazol-2-yl)5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] reduction assay was carried out to determine the viability of human uterine leiomyoma cells. Western blot analysis was done using anti pRB, anti-p21cip1/waf1, anti-p53, anti-cyclin E, anti CDK2 antibodies to detect the presence and expression of these proteins in treatment with resveratrol. DNA fragmentation assay was done to find the rate of apoptosis. Cell cycle analysis for resveratrol treated in human uterine leiomyoma cells was done by FACS (fluorescence-activated cell sorter) analysis.
RESULTS
Resveratrol induced growth inhibition in a dose dependent manner, treatment with 100 ?M/L resveratrol blocked 30% cell growth. From Western blot analysis it revealed resveratrol induced the expression of p53 increasing. Caspase pathway was activated and cleavage of PARP was occurred. Apoptosis took place but in a reduced manner. FACS results showed that resveratrol increased the percentage of cells in sub G1 phase.
CONCLUSION
Resveratrol, a dietry phytoalexin, inhibited cell proliferation and induced cell cycle arrest at sub G1 by enhancing the production of p53. These results indicate that resveratrol will be a promising agent chemopreventives or therapeutics against human uterine leiomyoma cells.

Keyword

Uterine leiomyoma cells; Resveratrol; Apoptosis

MeSH Terms

Antibodies
Apoptosis
Blotting, Western
Cell Cycle
Cell Cycle Checkpoints
Cell Proliferation
DNA Fragmentation
G1 Phase
Humans
Leiomyoma*
Antibodies
Full Text Links
  • KJOG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr